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ABSTRACT 
CD8+ T cell exhaustion is a hallmark of many cancers and chronic infections. In mice, 
T cell factor 1 (TCF-1) preserves the functionality of exhausted CD8+ T cells, 
whereas thymocyte selection-associated HMG box (TOX) is required for the 
epigenetic remodeling and survival of exhausted CD8+ T cells. However, it has 
remained unclear to what extent these transcription factors play analogous roles in 
humans. In this study, we mapped the expression of TOX and TCF-1 as a function of 
differentiation and specificity in the human CD8+ T cell landscape. Effector memory 
CD8+ T cells generally expressed TOX, whereas naive and early-differentiated 
memory CD8+ T cells generally expressed TCF-1. Cytolytic gene and protein 
expression signatures were also defined by the expression of TOX. In the context of 
a relentless immune challenge, exhausted human immunodeficiency virus (HIV)-
specific CD8+ T cells commonly expressed TOX, often in clusters with various 
activation markers and inhibitory receptors, and rarely expressed TCF-1. However, 
memory CD8+ T cells specific for cytomegalovirus (CMV) or Epstein-Barr virus (EBV) 
also expressed TOX, either with or without TCF-1. A similar phenotype was observed 
among HIV-specific CD8+ T cells from individuals who maintained exceptional 
immune control of viral replication. Collectively, these data suggest that TOX 
identifies exhausted and functionally replete human effector memory CD8+ T cells 
specific for chronic viruses, such as CMV, EBV, and HIV.  
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INTRODUCTION 
In the setting of many cancers and chronic viral infections, ongoing antigen exposure 
can lead to CD8+ T cell exhaustion, a phenomenon characterized by profound 
epigenetic and transcriptional changes associated with a progressive loss of effector 
functions and the upregulation of various inhibitory receptors (IRs). This process 
likely evolved to prevent excessive immune activation, but it remains a major 
stumbling block in the quest to develop more effective immunotherapies and 
vaccines. The functional consequences of exhaustion can be overcome to some 
extent via the administration of checkpoint inhibitors, which block signals transduced 
by IRs, such as CTLA-4 and PD-1. Although therapeutic interventions based on this 
concept have revolutionized the treatment of various cancers in recent years, clinical 
responses are unpredictable and vary considerably among individuals with the same 
diagnosis. A more detailed understanding of CD8+ T cell exhaustion is therefore 
required to inform translational efforts in the fields of immunoprophylaxis and 
immunotherapy (1).  
 
It is widely held that the process of exhaustion drives CD8+ T cells into a 
transcriptionally distinct lineage (1) that encompasses ‘precursor exhausted’ and 
‘terminally exhausted’ subsets within a unique differentiation spectrum (2). Precursor 
exhausted CD8+ T cells are thought to self-renew and differentiate into terminally 
exhausted CD8+ T cells, which display effector functionality. Direct comparison of 
these subsets has further shown that precursor exhausted CD8+ T cells less 
commonly express IRs and more commonly express certain transcription factors, 
including T cell factor 1 (TCF-1) (2). TCF-1 is a high mobility group (HMG) box 
transcription factor that plays a critical role in the differentiation and survival of 
memory CD8+ T cells under physiological conditions (3, 4). Moreover, TCF-1 
maintains stemness and sustains CD8+ T cell responses against chronic viral 
infections (5-7).  
 
There is no definitive marker that identifies exhausted CD8+ T cells. However, recent 
work has shown that the transcription factor thymocyte selection-associated HMG 
box (TOX) distinguishes exhausted from memory CD8+ T cells in various mouse 
models (8-12). These studies have demonstrated that TOX is absolutely required for 
the epigenetic remodeling and survival of exhausted CD8+ T cells (8-12). In the 
classic dichotomy, infection with lymphocytic choriomeningitis virus (LCMV) clone 13 
leads to chronic antigen stimulation and generates exhausted TOX+ virus-specific 
CD8+ T cell populations, which are clearly distinct from the memory CD8+ T cell 
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populations that emerge in response to infection with the non-persistent strain LCMV 
Armstrong (8, 9). Tumor-specific CD8+ T cells similarly express TOX and exhibit 
functional impairment associated with the upregulation of IRs (9, 10). It has 
nonetheless remained unclear how these data apply to acute and chronic viral 
infections in humans. This is a highly pertinent issue in the context of global health, 
because immune control of viral replication has been associated with the functional 
attributes of CD8+ T cells (13-17). 
 
Human immunodeficiency virus (HIV) infection is characterized by sustained viral 
replication and immune activation, leading to a progressive loss of CD4+ T cells and 
the eventual development of AIDS in the absence of antiretroviral therapy (ART). 
CD8+ T cells are essential for immune control of HIV (18). In a majority of cases, 
however, immune control is partial at best, and HIV-specific CD8+ T cells display the 
hallmarks of exhaustion, including dysfunctionality, impaired proliferation, and the 
expression of various IRs, such as PD-1, TIGIT, 2B4, CD39, and Tim-3 (13, 15, 19-
22). In contrast, rare individuals maintain highly functional HIV-specific CD8+ T cell 
populations, which associate with effective viral suppression (13, 23, 24). Specific 
transcription factors, such as Eomes and BATF, have previously been linked with 
CD8+ T cell exhaustion in the context of HIV infection (15, 25). It has nonetheless 
remained unclear to date how this process relates to the expression of TOX and 
TCF-1. 
 
We investigated the expression of TOX and TCF-1 as a function of differentiation and 
specificity in the human CD8+ T cell landscape. TOX was expressed primarily in 
effector memory CD8+ T cells, whereas TCF-1 was expressed primarily in naive and 
early-differentiated memory CD8+ T cells. Progressive HIV disease was associated 
with increased expression of TOX, together with various activation markers and IRs, 
and decreased expression of TCF-1. However, functionally replete CD8+ T cells 
specific for cytomegalovirus (CMV) or Epstein-Barr virus (EBV), which are controlled 
effectively by the immune system, also expressed intermediate to high levels of TOX. 
A similar pattern was observed for HIV-specific CD8+ T cells in cases where viral 
replication was controlled in the absence of ART. Collectively, these findings suggest 
a nuanced model in humans, wherein antigen-driven CD8+ T cell exhaustion is not 
necessarily defined solely by the expression of TOX.  
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RESULTS 
 
TOX and TCF-1 are differentially expressed among circulating CD8+ T cells 
Recent studies have examined the roles of TOX and TCF-1 in mouse models of 
chronic antigen-driven CD8+ T cell exhaustion (8-12). However, the expression 
patterns of these transcription factors, especially in combination, are less well 
defined in humans. To address this issue, we compared the transcriptomes of naive 
T (TN), central memory T (TCM), effector memory T (TEM), and effector memory RA T 
(TEMRA) cells flow-sorted directly ex vivo as phenotypically distinct CD8+ subsets from 
peripheral blood samples donated by HIV− individuals (Figure S1A). Analysis of the 
RNA-sequencing (RNA-seq) data revealed a core signature of genes that were 
differentially expressed among these CD8+ T cell subsets (Table S1). In particular, 
Tox and Tcf7, which encode TOX and TCF-1, respectively, were among the top 
identified genes that distinguished naive and memory CD8+ T cells (Figure 1A). Tox 
transcript levels were significantly elevated in TCM, TEM, and TEMRA cells relative to TN 
cells, whereas Tcf7 transcripts were significantly elevated in TN cells relative to TEM 
and TEMRA cells (Figure 1B). We then employed the Assay of Transposase-
Accessible Chromatin using sequencing (ATAC-seq) to characterize the epigenetic 
landscape of resting TN, TEM, and TEMRA cells. The Tox and Tcf7 loci both contained 
open chromatin clusters that distinguished TN cells from TEM and TEMRA cells (Figure 
1C). Importantly, TCF-1 binding motifs were more readily accessible in the open 
chromatin regions (OCRs) of TN cells relative to the OCRs of TEM and TEMRA cells 
(Figure 1D). Equivalent sequence-based analyses were not possible for TOX, which 
is thought to bind DNA in a structure-dependent manner (26). 
 
Differential expression of TOX and TCF-1 between naive and memory CD8+ T cells 
was validated at the protein level using Western blots (Figure 1E, S1B, and S1C). 
Flow cytometric analyses further confirmed that TOX was predominantly expressed 
in TEM and TEMRA cells, whereas TCF-1 was predominantly expressed in TN and TCM 
cells (Figure 1F). A previous study found that tonic antigen-driven stimulation 
triggered the expression of TOX (9). We corroborated this result and traced the 
expression patterns of TOX and TCF-1 in flow-sorted TN, TCM, TEM, and TEMRA cells 
labeled with a stable fluorescent dye. Most of the proliferating cells in each subset 
expressed TOX but not TCF-1 in response to stimulation via CD3 and CD28 (Figure 
1G and 1H).  
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Collectively, these results show that TOX and TCF-1 are differentially expressed and 
regulated among naive and memory subsets of human CD8+ T cells under 
physiological conditions. 
 
Expression of Tox and Tcf7 separates CD8+ T cells into distinct clusters 
To extend these findings, we analyzed a publicly available single-cell RNA-seq 
(scRNA-seq) dataset acquired from CD8+ T cells (10x Genomics Repository). Non-
linear relationships among individual CD8+ T cells were assessed using Uniform 
Manifold Approximation and Projection (UMAP). Tox and Tcf7 transcripts were 
readily detectable and distinctly expressed at the single-cell level (Figure 2A and 
S2A). We then binned CD8+ T cells into Tox+ and Tcf7+ events (Figure 2B). Tox+ cells 
expressed certain IR genes, including Pdcd1, Tigit, Cd244, and Lag3, whereas Tcf7+ 
cells expressed genes associated with naive and early-differentiated memory T cells, 
including Ccr7, Il7r, Sell, Nell2, Lef1, Bach2, Myc, and Id3 (Figure 2B and S2B). 
Multiple effector memory genes were also differentially expressed between Tox+ and 
Tcf7+ cells, including Gzmb, Gzma, Prf1, Cx3cr1, Tbx21, Eomes, Zeb2, and Prdm1 
(Figure 2B and Table S2).  
 
Further analysis of the same dataset using Seurat identified eight different clusters 
on the basis of differential gene expression (Figure 2C). Two naive-like clusters (0 
and 1) with the highest expression levels of Tcf7 also expressed high levels of Ccr7, 
Lef1, and Sell (Table S3). In contrast, three effector memory-like clusters (5, 6, and 
7) with the highest expression levels of Tox were enriched for effector-related genes, 
including Ccl5, Gzma, Nkg7, Gzmh, Klrd1, Prf1, Gnly, and Fgfbp2 (Figure 2D and 
Table S3). Although not part of the core signature, certain IR genes, including Pdcd1, 
Tigit, Lag3, and Lilrb1, were also prefentially expressed among these Tox+ clusters 
(Figure S3).  
 
Collectively, these findings highlight an association between Tox and the expression 
of genes that encode various immune cell effector proteins and IRs.  
 
TOX and TCF-1 are expressed in CD8+ T cell clusters 
To validate the scRNA-seq data acquired from CD8+ T cells, we designed a 28-color 
flow cytometry panel to assess the expression of differentially regulated transcripts at 
the protein level in relation to TOX and TCF-1. Data were again concatenated and 
analyzed using UMAP (Figure S3A and S3B). Manual gating identified TN, TCM, TEM, 
and TEMRA clusters in the UMAP space (Figure 3A). Distinct topographical regions 
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were then delineated by overlaying the expression of TOX and TCF-1 (Figure 3B). 
Phenograph analysis revealed 27 unique cell clusters in the UMAP space (Figure 3C 
and S3C). TCF-1 was coexpressed with CCR7, CD45RA, and CD28 (Figure 3D). In 
contrast, TOX was expressed in clusters with increased expression of cytolytic 
proteins, namely granzyme B (GzmB) and perforin, and certain IRs, including PD-1, 
TIGIT, 2B4, and CD39 (Figure 3E). Moreover, specific TOX clusters exhibited high 
expression levels of cytolytic proteins (cluster 5), IRs (cluster 27), or both cytolytic 
proteins and IRs (cluster 26) (Figure 3E). Manual gating analysis further confirmed 
that almost every single TOX+ cell expressed GzmB, perforin, PD-1, TIGIT, or 2B4 
(Figure S3C).  
 
Although TOX and TCF-1 were largely expressed in different cell clusters, we also 
identified a progenitor-like TOX+TCF-1+ population and a highly differentiated 
TOX+TCF-1− population (Figure 3F). TOX+TCF-1+ cells expressed higher levels of 
the early differentiation markers CCR7 and CD28, as well as some IRs (PD-1 and 
TIGIT), relative to TOX+TCF-1− cells, whereas TOX+TCF-1− cells expressed higher 
levels of perforin, GzmB, CD38, 2B4, and Tim-3 relative to TOX+TCF-1+ cells (Figure 
3F). GzmB+perforin+ cells were also more prevalent than either GzmB+perforin− or 
GzmB−perforin− cells in the TOX+TCF-1− compartment (Figure S3D).  
 
Collectively, these observations demonstrate the existence of distinct TOX+ 
subpopulations in the CD8+ T cell landscape, some of which lack expression of IRs. 
 
HIV infection is associated with increased expression of TOX  
To understand how an ongoing systemic infection impacts the balance between TOX 
and TCF-1 expression in human memory CD8+ T cells, we recruited HIV+ viremic 
individuals and HIV+ aviremic individuals on ART (Table S4). In line with previous 
studies (15, 19, 22, 25), we found that some IRs, including PD-1, TIGIT, and 2B4, 
were expressed at higher frequencies on memory CD8+ T cells from HIV+ viremic 
donors relative to HIV− donors (Figure 4A). Circulating memory CD8+ T cells also 
more commonly expressed TOX and less commonly expressed TCF-1 in the context 
of HIV (Figure 4B). Increased frequencies of TOX+TCF-1− cells were detected in HIV+ 
viremic donors relative to HIV− and HIV+ aviremic donors (Figure 4B). A similar 
pattern was observed for TOX−TCF-1− cells (Figure 4B), which typically displayed 
high levels of activation (data not shown). Moreover, TOX+TCF-1+ cells persisted at 
elevated frequencies in HIV+ aviremic donors relative to HIV− donors, whereas HIV− 
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donors harbored increased frequencies of TOX−TCF-1+ cells relative to HIV+ viremic 
and HIV+ aviremic donors (Figure 4B). 
 
Memory CD8+ T cells that expressed PD-1, TIGIT, or 2B4 mostly coexpressed TOX, 
both in the absence and presence of actively replicating HIV (Figure 4C). However, 
PD-1+TIGIT+2B4+ cells were more heavily skewed toward a TOX+TCF-1− phenotype 
in HIV+ viremic donors relative to HIV− donors (Figure S4A). We also noted that many 
TOX+ cells expressed cytolytic molecules and that not all TOX+ cells expressed IRs 
(Figure 4D).  
 
In further analyses, we concatenated the multiparametric data and compared 
memory CD8+ T cells from HIV− donors with memory CD8+ T cells from HIV+ viremic 
donors via UMAP (Figure 4E). A balanced TOX versus TCF-1 expression pattern 
was observed in HIV− donors, whereas a skewed TOX+ phenotype was found in HIV+ 
viremic donors (Figure 4E and 4F). Specific markers that distinguished TOX+ and 
TCF-1+ clusters (Figure 3) were then analyzed using Phenograph (Figure 4F and 
S5B). Again, TCF-1 was coexpressed with CCR7 and CD28, whereas TOX was 
expressed in clusters with increased expression of cytolytic proteins and/or IRs 
(Figure 4G). Memory CD8+ T cells from HIV− donors were found commonly in 
clusters with high expression levels of TCF-1 (clusters 17 and 9) and occasionally in 
clusters with detectable expression levels of TOX (clusters 18 and 10) (Figure 4H 
and 4I). TOX+ clusters in HIV− donors nonetheless tended to express lower levels of 
PD-1, TIGIT, and CD38 relative to TOX+ clusters in HIV+ viremic donors (clusters 20, 
2, 4, 6, 13, 3, 11, 23, 1, and 21), whereas the dominant TOX+ clusters in HIV+ viremic 
donors expressed higher levels of cytolytic proteins and IRs relative to the dominant 
TOX+ clusters in HIV− donors (Figure 4H and 4I).  
 
Collectively, these data show that memory CD8+ T cells are skewed into a continuum 
of TOX+ phenotypes in the setting of chronic infection with HIV. 
 
Memory CD8+ T cells specific for chronic viral antigens express TOX 
Studies in mice have investigated the expression of TOX and TCF-1 in LCMV 
infection models (8, 9, 12). However, it has remained unclear whether viral infections 
induce the expression of TOX in human CD8+ T cells, which are similarly prone to 
antigen-driven exhaustion via a process that is not necessarily associated with the 
expression of IRs (17, 27). We therefore investigated the expression of TOX and 
TCF-1 in human CD8+ T cell populations specific for influenza virus (Flu), which 
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establishes acute infections, CMV or EBV, which establish persistent infections 
controlled by the immune system, or HIV, which establishes persistent infections and 
continues to replicate vigorously in the absence of ART (Figure 5A and S5C). In line 
with studies of mice infected with LCMV (8, 9, 12), we found that Flu-specific CD8+ T 
cells rarely expressed TOX and commonly expressed TCF-1, whereas CD8+ T cells 
specific for CMV, EBV, or HIV commonly expressed TOX with or without TCF-1 
(Figure 5B and S5D).  
 
Data concatenation and UMAP visualization revealed specificity-based clustering of 
CD8+ T cells (Figure 5C). Flu-specific CD8+ T cells were found mainly in cluster 9, 
which displayed high expression levels of TCF-1 and CCR7 and low to intermediate 
expression levels of TOX, cytolytic proteins, and IRs (Figure 4H, 5D, and 5E). Many 
EBV-specific CD8+ T cells also localized to cluster 9, but additional clusters were 
identified with detectable expression of TOX and variable expression levels of 
cytolytic proteins and IRs (clusters 12, 10, 2, 4, 6, 7, and 8) (Figure 4H, 5D, and 5E). 
In contrast, CMV-specific CD8+ T cells predominated in clusters with high expression 
levels of TOX and cytolytic proteins and intermediate to high expression levels of IRs 
(clusters 11, 18, 21, and 23), whereas HIV-specific CD8+ T cells were most prevalent 
in clusters 1, 2, 3, 4, 5, and 6, which displayed high expression levels of TOX, low to 
intermediate expression levels of TCF-1, and variable expression levels of cytolytic 
proteins and IRs (Figure 4H, 5D, and 5E).  
 
To determine the functional relevance of TOX, we stimulated PBMCs with pools of 
peptides corresponding to known optimal epitopes derived from Flu, CMV, EBV, and 
HIV and measured GzmB and perforin alongside surface mobilization of CD107a and 
the intracellular production of IFN-g, TNF, and IL-2. Virus-specific CD8+ T cells that 
produced IL-2, an early-differentiated function, rarely expressed TOX, whereas virus-
specific CD8+ T cells that were loaded with cytolytic proteins and produced the 
effector cytokines IFN-g and TNF commonly expressed TOX (Figure 5F). 
 
Collectively, these observations demonstrate that CD8+ T cells with different 
functional profiles and viral specificities occupy distinct phenotypic niches with 
differential expression of TOX and TCF-1. 
 
HIV-specific memory CD8+ T cells from elite controllers exhibit increased 
expression of TCF-1 
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To correlate these findings with immune efficacy, we recruited HIV+ elite controllers 
(ECs), defined as individuals who maintain undetectable levels of plasma viral RNA 
in the absence of ART (Table S4). As expected, we found that PD-1, CD38, and 
CD39 were expressed at higher frequencies among HIV-specific CD8+ T cells from 
HIV+ viremic donors relative to HIV-specific CD8+ T cells from ECs (Figure 6A). 
Irrespective of disease status, a vast majority of HIV-specific CD8+ T cells expressed 
TOX (Figure 6B). However, TCF-1+ cells were present at higher frequencies among 
HIV-specific CD8+ T cells from ECs relative to HIV-specific CD8+ T cells from HIV+ 
viremic donors (Figure 6B).  
 
In response to cognate peptide stimulation, higher frequencies of HIV-specific CD8+ 
T cells from ECs produced TNF and IL-2 relative to HIV-specific CD8+ T cells from 
either HIV+ viremic donors or HIV+ aviremic donors on ART (Figure 6C and S6A). 
Moreover, TNF+ HIV-specific CD8+ T cells expressed lower levels of TOX on a per 
cell basis relative to TNF− HIV-specific CD8+ T cells (Figure S6B), IL-2+ HIV-specific 
CD8+ T cells expressed lower levels of TOX and higher levels of TCF-1 on a per cell 
basis relative to IL-2− HIV-specific CD8+ T cells, and CD107a+ HIV-specific CD8+ T 
cells expressed lower levels of TCF-1 on a per cell basis relative to CD107a− HIV-
specific CD8+ T cells (Figure 6C). In addition, most GzmB+perforin+IFN-g+ HIV-
specific CD8+ T cells expressed TOX without TCF-1, whereas most IL-2+ HIV-specific 
CD8+ T cells expressed TCF-1 (Figure 6D).  
 
Collectively, these results identify a functional dichotomy associated with the 
differential expression of TOX and TCF-1 that correlates with immune control of HIV. 
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DISCUSSION 
In this study, we investigated the extent to which two HMG box transcription factors, 
TOX and TCF-1, shape the processes of exhaustion and memory differentiation 
among subpopulations of human CD8+ T cells. Under physiological conditions, 
effector memory CD8+ T cells primarily expressed TOX, whereas naive and early-
differentiated memory CD8+ T cells primarily expressed TCF-1. Cytolytic gene and 
protein expression signatures among lymphocyte lineages in general were also 
defined by the expression of TOX. In the context of ongoing viral replication, 
dysfunctional HIV-specific CD8+ T cells commonly expressed TOX, which clustered 
with various activation markers and IRs, and rarely expressed TCF-1. However, 
functionally competent memory CD8+ T cells specific for CMV or EBV also expressed 
TOX. A similar phenotype was observed among HIV-specific CD8+ T cells from ECs.  
 
TOX and TCF-1 were originally described as transcriptional regulators of lymphocyte 
development and maturation (28-31). More recent studies have shown that TOX is 
expressed in most exhausted CD8+ T cells specific for various cancers and chronic 
viruses (8-12), whereas TCF-1 is upregulated in precursor exhausted CD8+ T cells 
(5-7). Importantly, TOX and TCF-1 are both required for the survival of murine CD8+ 
T cells that recognize chronic viral antigens (8, 12). In humans, TCF-1 has been 
associated with early-differentiated CD8+ T cells (32, 33), whereas TOX has been 
associated with exhuasted CD8+ T cells (8, 9, 34, 35). However, these correlative 
studies did not assess both transcription factors simultaneously in relation to different 
aspects of CD8+ T cell immunobiology. We identified three discrete memory CD8+ T 
cell populations in humans based on the expression of TOX and TCF-1. Early-
differentiated TCM and TEM cells displayed a TOX−TCF-1+ phenotype with negligible 
expression of IRs. A vast majority of Flu-specific CD8+ T cells were encapsulated 
within this population, consistent with the acute memory phenotype described in mice 
infected with LCMV (9). Most healthy donors also harbored a progenitor-like 
TOX+TCF-1+ subset, which commonly expressed CCR7 and CD28, and an effector-
like TOX+TCF-1− subset, characterized by the expression of cytolytic proteins. 
Moreover, IRs were expressed primarily in conjunction with TOX, but not all TOX+ 
cells expressed IRs. This observation suggests that exhaustion per se is not 
necessarily defined solely by TOX. Indeed, we found that TOX was frequently 
expressed in CMV-specific CD8+ T cells, which are highly cytolytic and functionally 
replete (15, 36, 37). These effector properties have also been shown to confer 
protection against simian immunodeficiency virus in nonhuman primate models (38, 
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39). Accordingly, TOX appears to define biologically protective human effector 
memory CD8+ T cells, driven to a functional optimum by CMV. 
 
In contrast to laboratory mice, humans are commonly infected with many different 
chronic viruses, including herpesviruses, such as CMV and EBV, polyomaviruses, 
and endogenous retroviruses (40). Ongoing antigen exposure is therefore likely 
universal across various specificities in healthy donors, potentially explaining the 
widespread occurrence of TOX+ memory CD8+ T cells. These less virulent chronic 
viruses have evolved in synergistic equilibrium with the host, such that the human 
immune system as it exists today represents the unfinished product of countless 
adaptations over millions of years (41). Accordingly, TOX may serve as a positive 
regulator of survival that maintains highly functional and protective CD8+ T cell 
responses directed against ineradicable pathogens (17, 42, 43).  
 
Previous studies have shown that exhaustion is stably imprinted at the epigenetic 
level (17, 43). Our data support the notion that a similar phenomenon applies in the 
case of TOX. For example, we found that HIV-specific CD8+ T cells expressed TOX 
more commonly than Flu-specific CD8+ T cells, even in donors with low plasma 
burdens of viral RNA. In addition, TOX was expressed less frequently in CD8+ T cells 
from HIV− donors relative to CD8+ T cells from HIV+ aviremic donors on ART. Of 
particular note, we also found that TCF-1 was expressed at relatively high 
frequencies alongside TOX in HIV-specific CD8+ T cells from ECs. These cells 
typically produce multiple cytokines and proliferate vigorously in response to antigen 
encounter (13, 16). Moreover, we noted that IL-2 production was associated with 
increased expression levels of TCF-1 and decreased expression levels of TOX, 
whereas most cytolytic HIV-specific CD8+ T cells displayed a TOX+TCF-1− 
phenotype. A functional spectrum of HIV-specific CD8+ T cells can therefore be 
defined based on the transcription factors TOX and TCF-1. 
 
Our collective dataset provides an expression atlas for TOX and TCF-1 in the human 
CD8+ T cell landscape under physiological conditions and under challenge from a 
relentless pathogen. Importantly, we found that TOX demarcates cytolytic effector 
CD8+ T cells, which reside primarily in the TEM and TEMRA compartments, as well as 
exhausted CD8+ T cells. On the basis of these findings, we propose that TOX is a 
universal regulator of human memory CD8+ T cells specific for chronic viruses, such 
as CMV, EBV, and HIV.   
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MATERIALS AND METHODS 
 
Samples 
Peripheral blood was collected from individuals classified as HIV− (n = 30), HIV+ 
viremic (VL > 1,000 RNA copies/mL; n = 23), HIV+ aviremic on ART (VL < 50 RNA 
copies/mL for > 1 year; n = 17), and HIV+ elite controllers (VL < 50 RNA copies/mL 
for at least three consecutive visits in the absence of ART; n = 10). Recruitment 
occurred at four sites under protocols approved by the relevant Institutional Review 
Boards: Karolinska University Hospital (Stockholm, Sweden), Asociación Civil 
Impacta Salud y Educación (Lima, Peru), University of Alabama at Birmingham 
(Birmingham, AL, USA), and Massachusetts General Hospital (Boston, MA, USA). All 
samples were collected in accordance with the principles of the Declaration of 
Helsinki. Donor groups and clinical parameters are summarized in Table S4. 
 
Flow cytometry 
PBMCs were isolated from whole blood via standard density gradient centrifugation 
and cryopreserved in liquid nitrogen. Cryopreserved PBMC samples were thawed, 
resuspended at 2 x 106 cells/mL, and rested overnight at 37°C in complete medium 
(RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% L-glutamine, 
and 1% penicillin/streptomycin) in the presence of 10 U/mL DNAse I (Roche) as 
described previously (15, 44, 45). Cells were then washed in fluorescence-activated 
cell sorting (FACS) buffer (phosphate-buffered saline [PBS] supplemented with 2% 
fetal bovine serum and 2 μM EDTA) and stained with MHC class I tetramers and/or a 
directly conjugated antibody specific for CCR7 (clone G043H7, BioLegend) for 10 
minutes at 37°C. Other surface markers were detected via the subsequent addition 
of an optimized panel of directly conjugated antibodies for 20 minutes at room 
temperature, and viable cells were identified by exclusion using a LIVE/DEAD 
Fixable Aqua Dead Cell Stain Kit (Thermo Fisher Scientific). Cells were then washed 
again in FACS buffer and fixed/permeabilized using a FoxP3 / Transcription Factor 
Staining Buffer Set (eBioscience). Intracellular markers were detected via the 
subsequent addition of an optimized panel of directly conjugated antibodies for 1 
hour at 4°C. Stained cells were fixed in PBS containing 1% paraformaldehyde 
(Biotium) and stored at 4°C. All samples were acquired within 24 hours using a 
FACSymphony A5 (BD Biosciences). Data were analyzed with FlowJo software 
version 10.6.1 (FlowJo LLC). 
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Antibodies 
Directly conjugated antibodies with the following specificities were used in flow 
cytometry experiments: CD3–BV605, CD3–BV650, or CD3–BUV805 (clone UCHT1), 
CD8–BUV395 (clone RPA-T8), CD14–APC-Cy7 (clone MfP9), CD15–BUV395 
(clone W6D3), CD16–A700 (clone 3G8), CD19–BUV737 (clone SJ25C1), CD28–
BUV563 (clone CD28.2), CD38–BUV496 (clone HIT2), CD49a–BUV615 (clone 
SR84), CD69–BV750 (clone FN50), CD95–BB630 (clone DX2), CD107a–PE-CF594 
(clone H4A3), CXCR5–APC-R700 (clone RF8B2), granzyme B–A700 or granzyme 
B–BB790 (clone GB11), IFN-g–FITC or IFN-g–PE (clone B27), IL-2–APC-R700 
(clone MQ1-17H12), Ki-67–BB660 (clone B56), Lag-3–BUV661 (clone T47-530), 
perforin–BB700 (clone dG9), TCRgd–PE-CF594 (clone B1), TIGIT–BUV737 (clone 
741182), and TNF–BV650 (clone Mab11) from BD Biosciences; CCR7–APC-Cy7 
(clone G043H7), CD8–BV570 or CD8–BV605 (clone RPA-T8), CD14–BV510 (clone 
M5E2), CD19–BV510 (clone HIB19), CD45RA–BV570 or CD45RA–BV650 (clone 
HI100), CD39–BV711 (clone A1), CD56–BV711 (clone HCD56), CD103–BV605 
(clone Ber-ACT8), CD127–BV421 or CD127–BV785 (clone A019D5), CD161–BV605 
(clone HP-3G10), PD-1–PE-Cy7 (clone EH12.2H7), perforin–BV421 (clone B-D48), 
Tim-3–BV650 (clone F38-2E2), TCR Va7.2–PE (clone 3C10), and 2B4–PE/Dazzle 
594 (clone C1.7) from BioLegend; TCF-1–AF488 or TCF-1–PE (clone C63D9) from 
Cell Signaling Technology; TOX–AF647 (clone REA473) from Miltenyi Biotec; and 
CD4–PE-Cy5.5 (clone S3.5) and CD25–PE-Cy5 (clone CD25-3G10) from Thermo 
Fisher Scientific. 
 
Peptides  
Pools of peptides corresponding to known optimal epitopes derived from CMV (n = 
14), EBV (n = 26), Flu (n = 17), and HIV (n = 22) were purchased from Peptides & 
Elephants GmbH. All peptides were synthesized at a purity of > 95%. Lyophilized 
peptides were reconstituted at 100 mg/mL in DMSO and further diluted to 100 µg/mL 
in PBS.  
 
Tetramers 
MHC class I tetramers conjugated to BV421 or PE were used to detect CD8+ T cells 
with the following specificities: CMV NLVPMVATV (NV9/HLA-A*0201), EBV 
GLCTLVAML (GL9/HLA-A*0201), Flu GILGFVFTL (GL9/HLA-A*0201), HIV 
FLGKIWPSHK (FK10/HLA-A*0201), HIV ILKEPVHGV (IV9/HLA-A*0201), HIV 
SLYNTVATL (SL9/HLA-A*0201), EBV RVRAYTYSK (RK9/HLA-A*0301), Flu 
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RVLSFIKGTK (RK10/HLA-A*0301), CMV QYDPVAALFL (QL10/HLA-A*2402), EBV 
TYGPVFMCL (TL9/HLA-A*2402), HIV KYKLKHIVW (KW9/HLA-A*2402), HIV 
RYPLTFGW (RW8/HLA-A*2402), CMV TPRVTGGGAM (TM10/HLA-B*0702), HIV 
GPGHKARVL (GL9/HLA-B*0702), EBV RAKFKQLL (RL8/HLA-B*0801), HIV 
EIYKRWII (EI8/HLA-B*0801), HIV KRWIILGLNK (KK10/HLA-B*2705), HIV 
ISPRTLNAW (IW9/HLA-B*5701), HIV KAFSPEVIPMF (KF11/HLA-B*5701), and HIV 
QASQEVKNW (QW9/HLA-B*5701). All tetramers were generated in house as 
described previously (46). 
 
Functional assays 
PBMCs were seeded in complete medium at 2 x 106 cells/mL in 96-well V-bottom 
plates (Corning) with unconjugated anti-CD28 (clone L293) and anti-CD49d (clone 
L25) (each at 3 µL/mL; BD Biosciences), brefeldin A (1 µL/mL; Sigma-Aldrich), 
monensin (0.7 µL/mL; BD Biosciences), anti-CD107a–PE-CF594 (clone H4A3; BD 
Biosciences), and the relevant viral peptides (each at a final concentration of 0.5 
µg/mL). Unstimulated negative controls were included in each assay. Cells were 
analyzed by flow cytometry after incubation for 6 hours at 37°C. 
 
Proliferation assay 
CD8+ T cell subsets were flow-sorted using a MA900 Multi-Application Cell Sorter 
(Sony Biotechnology), labeled with CellTrace Violet (0.5 µM; Thermo Fisher 
Scientific), and resuspended in complete medium in 96-well U-bottom plates 
(Corning) with IL-2 (100 IU/mL; PeproTech) and ImmunoCult Human CD3/CD28 T 
Cell Activator (5 µL/mL; STEMCELL Technologies). IL-2 was replenished on day 3. 
Cells were analyzed by flow cytometry after incubation for 5 days at 37°C. 
 
Activation of the calcineurin pathway 
Naive CD8+ T cells were cultured in complete medium at various densities with 
ImmunoCult Human CD3/CD28 T Cell Activator (5 µL/mL; STEMCELL Technologies) 
or ionomycin (100 ng/mL; Sigma-Aldrich) and/or phorbol myristate acetate (10 
ng/mL; Sigma-Aldrich). Unstimulated negative controls were included in each assay. 
Cells were analyzed by flow cytometry after incubation for 24 hours at 37°C. 
 
UMAP and PhenoGraph  
FCS3.0 data files were imported into FlowJo software version 10.6.0 (FlowJo LLC). 
All samples were compensated electronically. Dimensionality reduction was 
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performed using the FlowJo plugin UMAP version 2.2 (FlowJo LLC). The 
downsample version 3.0.0 plugin and concatenation tool was used to visualize 
multiparametric data from comparable numbers of total CD8+ T cells per healthy 
donor (n = 4). Comparable numbers of memory CD8+ T cells from HIV− (n = 2) and 
HIV+ individuals (n = 2) were similarly applied to UMAP. The following parameters 
were used in these analyses: metric = euclidean, nearest neighbors = 15, and 
minimum distance = 0.5. Clusters of phenotypically related cells were then detected 
using Phenograph version 0.2.1. The following markers were considered in each 
case: CCR7, CD25, CD28, CD38, CD39, CD45RA, CD49a, CD95, CD103, CXCR5, 
granzyme B, Ki-67, Lag-3, perforin, PD-1, TCF-1, TIGIT, Tim-3, TOX, and 2B4. 
Phenograph clustering was performed using the coordinates from UMAP. Plots were 
generated using Prism version 8.2.0 (GraphPad Software Inc.). 
 
RNA-seq 
Naive and memory CD8+ T cells (250 cells/subset) were flow-sorted directly into lysis 
buffer using a FACSAria II (BD Biosciences). RNA-seq libraries were prepared from 
snap-frozen lysates using a SMART-Seq v4 Ultra Low Input RNA Kit (Takara). 
Briefly, 3’ oligo-dt primers were hybridized to the poly(A) tails of mRNA molecules, 
and cDNA was generated using SMARTScribe Reverse Transcriptase (Takara) and 
preamplified using SeqAmp DNA Polymerase (Takara). Cleanup was performed 
using Agencourt AMPure XP Beads (Beckman Coulter). cDNA was quantified using 
Qubit 3.0 (Thermo Fisher Scientific), and fragment sizes were evaluated using a 
2100 BioAnalyzer (Agilent). PCR products were then indexed using a Nextera XT 
DNA Library Prep Kit (Illumina). Briefly, transcripts were tagmented using Amplicon 
Tagment Mix (Illumina) and indexed using a Nextera Index Kit (Illumina). Cleanup 
was performed again using Agencourt AMPure XP Beads (Beckman Coulter). 
Libraries were pooled, quantified, and sequenced across 75 base pairs (bp) using a 
paired-end approach with a 150-cycle high-output flow cell on a NextSeq 550 
(Illumina). Three biological replicates were sequenced per experiment. Fastq files 
from replicate sequencing runs were concatenated and aligned using STAR software 
version 2.5.2a and hg38. Depth ranged from 8 million to 13.6 million reads per 
sample. Raw counts were normalized using DESeq2 (Bioconductor). Normalized 
data were then transformed to Z-scores and analyzed for differential expression 
using the limma package in R. 
 
ATAC-seq 
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Naive and memory CD8+ T cells (30,000–50,000 cells/subset) were flow-sorted 
directly into complete medium using a FACSAria II (BD Biosciences). ATAC-seq was 
carried out as described previously (45). Briefly, cells were pelleted, washed in PBS, 
and treated with lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 
0.1% IGEPAL CA-630). Nuclear pellets were resuspended in transposition buffer 
containing Tn5 transposase (Illumina) for 30 minutes at 37°C. Tagmented DNA was 
purified using a MinElute Reaction Cleanup Kit (Qiagen). Amplified libraries were 
purified using a QIAQuick PCR Purification Kit (Qiagen) and subjected to paired-end 
sequencing (38 bp + 37 bp) on a NextSeq 550 (Illumina). Two biological replicates 
were sequenced per experiment. ATAC-seq peaks were called out in each replicate 
using the (-p 1e-7 --nolambda --nomodel) function in MACS2. A read count table was 
generated and used to identify differentially enriched regions among subsets using 
DESeq2 with the parameters fold change > 2 and P < 0.05. De novo Tcf7 and Tox 
motif analyses were carried out using HOMER. Peaks were visualized using 
Integrative Genomics Viewer software version 2.3.93.  
 
Single-cell RNA-seq 
Single-cell RNA-seq data were acquired from the 10x Genomics Repository 
(https://support.10xgenomics.com/single-cell-vdj/datasets/). Expression matrices 
were reconstructed from Feature-Barcode Matrices (https://github.com/Jx-
b/10x_notebooks/blob/master/CellRanger%20output%20processing.ipynb). UMAP 
plots and differential gene expression profiles were generated using the Loupe Cell 
Browser (10x Genomics). Four healthy donors were analyzed for differential 
expression of genes between the Tox+Tcf7− and Tox−Tcf7+ CD8+ T cell subsets (total 
n = 245,883 CD8+ T cells). Heatmaps and violin plots were generated from Tox+ (n = 
3,187) and Tcf7+ CD8+ T cells (n = 12,952) using the Python Open Source Graphing 
Library (Plotly). Lineage analyses were conducted using a total of 7,865 PBMCs. 
Raw read counts were analyzed using Monocle 3 (47-49). Data were processed 
using the “preprocess_cds” function (num_dim = 100). The number of dimensions 
was reduced using “reduce_dimension”, and cells were clustered using 
“cluster_cells”. UMAP plots were generated using “plot_cells” (with 
“scale_colour_distiller” overwrite for plots containing overlays of specific gene 
expression). Pseudotime trajectories were generated using “learn_graph”. 
 
Western blot 
Naive and memory CD8+ T cells were sorted either directly or after stimulation into 
complete medium using a MA900 Multi-Application Cell Sorter (Sony Biotechnology). 
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Cells were then pelleted, washed twice in ice-cold PBS, and lyzed in RIPA Lysis and 
Extraction Buffer (Thermo Fisher Scientific). Protein content was quantified using a 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Normalized amounts of 
protein in PBS were mixed with 4x loading buffer (62.5 mM Tris-HCl pH 6.8, 2% [w/v] 
SDS, 10% glycerol, 0.04 M DTT, and 0.01% [w/v] bromophenol blue) and heated for 
10 minutes at 90°C. Equal volumes were loaded onto 10% Precast Polyacrylamide 
Gels (Bio-Rad). Gel electrophoresis was performed for 60 minutes at 130 V. Proteins 
were transferred to a polyvinylidene fluoride membrane over 1 hour at 100 V using a 
Mini-PROTEAN Tetra Cell and Mini Trans-Blot Module (Bio-Rad). Membranes were 
blocked with 5% skimmed milk in TBS-T (150 mM NaCl, 10 mM Tris-HCl pH 7.5, 
0.1% Tween-20) and incubated with the relevant antibodies overnight at 4°C. The 
following antibodies were used in these experiments: anti-GAPDH (clone 6C5) 
diluted at 1:2,000 (Abcam), anti-TCF1 (clone 655202) diluted at 1:1,000 (BioLegend), 
and anti-TOX (rabbit polyclonal ab155768) diluted at 1:700 (Abcam). Membranes 
were then washed in TBS-T, incubated with secondary antibodies conjugated to 
horseradish peroxidase (diluted at 1:4,000) for 1 hour at room temperature, and 
developed using West Femto Maximum Sensitivity Substrate (Thermo Fisher 
Scientific). Antibody dilutions were prepared using 2% milk in TBS-T. Blots were 
imaged using a G:BOX Imaging System (Syngene). 
 
Statistics 
Differences between unmatched groups were compared using an unpaired t-test or 
the Mann-Whitney U test, and differences between matched groups were compared 
using a paired t-test or the Wilcoxon signed-rank test. Correlations were assessed 
using the Pearson correlation or the Spearman rank correlation. Non-parametric 
tests were used if the data were not distributed normally according to the Shapiro-
Wilk normality test. All analyses were performed using R studio or Prism 7.0 
(GraphPad). Phenotypic relationships within multivariate data sets were visualized 
using FlowJo software version 10.6.1 (FlowJo LLC). 
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Figure 1. Expression of Tox and Tcf7 in CD8+ T cell subsets. (A) RNA-seq 
heatmap showing differentially expressed genes (fold change > 2; P < 0.05) among 
TN, TCM, TEM, and TEMRA cells (n = 3 healthy donors). (B) Volcano plots comparing 
gene expression between TN cells and each subset of memory CD8+ T cells (n = 1 
healthy donor). (C) ATAC-seq tracks showing enrichment of OCRs adjacent to Tox 
(top) and Tcf7 (bottom) for TN, TEM, and TEMRA cells (n = 1 healthy donor). (D) 
Enrichment of the Tcf7 motif in OCRs comparing TN versus TEM cells and TN versus 
TEMRA cells (n = 1 healthy donor). (E) Western blot analysis of TOX expression in TN 
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versus memory (non-naive) CD8+ T cells. Actin was included as a loading control. (F) 
Representative histograms and donor-matched graphs showing percent expression 
of TOX and TCF-1 in TN, TCM, TEM, and TEMRA cells.  (G) Expression of TOX and TCF-
1 in TN, TCM, TEM, and TEMRA cells after stimulation with ImmunoCult Human 
CD3/CD28 T Cell Activator for 5 days (aCD3/CD28). NC, negative control. (H) 
Details as in G. Proliferating cells were identified using CellTrace Violet (CTV). 
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Figure 2. Expression of Tox and Tcf7 in the CD8+ T cell landscape. (A) scRNA-
seq analysis of circulating CD8+ T cells (n = 2 healthy donors). The UMAP plot 
illustrates the distribution of Tox+ (>1 read) and Tcf7+ cells (>1 read). (B) Violin plots 
showing immune-related genes that were differentially expressed between Tox+ and 
Tcf7+ cells (n = 2 healthy donors). Differentially expressed genes were identified 
using a threshold of P < 0.05. (C) Clustering analysis of the same dataset using 
Seurat. (D) Heatmap showing genes that were differentially expressed among the 
clusters identified in C. Highlighted genes encode proteins with known differential 
expression between naive and memory T cell subsets.  
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Figure 3. Expression of TOX and TCF-1 in CD8+ T cell clusters. 
(A) Left: flow cytometric gating strategy for the identification of TN, TCM, TEM, and 
TEMRA cells. Right: subset distribution on the UMAP plot generated from bulk CD8+ T 
cells after data concatenation (n = 4 healthy donors). (B) Left: expression of TOX and 
TCF-1 in bulk CD8+ T cells. Right: expression intensities projected on the 
corresponding UMAP plots. (C) The same UMAP display with subpopulations 
colored using Phenograph (n = 27 clusters). (D) UMAP plots showing expression 
patterns for the indicated markers. (E) Hierarchical clustering of expression intensity 
(z-score) for each of the indicated markers in each cluster derived using 
Phenograph. (F) Top left: flow cytometric gating strategy for the separation of TOX+ 
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cells into TCF-1− and TCF-1+ populations. Top right: histograms showing expression 
of the indicated markers among TOX+TCF-1+ (red) and TOX+TCF-1− cells (blue). 
Bottom: scatter plots showing expression frequencies for the indicated markers 
among TOX+TCF-1+ and TOX+TCF-1− cells from all healthy donors. *P < 0.05, **P < 
0.01, ***P < 0.001. 
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Figure 4. Expression of TOX and TCF-1 in donors infected with HIV. (A) 
Expression of the indicated IRs on memory CD8+ T cells from a representative HIV− 
donor (blue boxes) and a representative HIV+ viremic donor (red boxes). (B) Left: 
expression of TOX and TCF-1 in memory CD8+ T cells. Right: scatter plots showing 
TOX+/−TCF-1+/− population frequencies among memory CD8+ T cells from HIV− 
(blue), HIV+ viremic (red), and HIV+ aviremic donors (yellow). (C) Left: coexpression 
of TOX versus PD-1, TIGIT, and 2B4 among memory CD8+ T cells from a 
representative HIV− donor (top) and a representative HIV+ viremic donor (bottom). 
Right: stack bars showing the frequencies of TOX− and TOX+ cells among IR+ 
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memory CD8+ T cells (n = 30 HIV− donors in blue and n = 17 HIV+ viremic donors in 
red). (D) Left: coexpression of PD-1 versus GzmB among CD8+ T cells pre-gated on 
TOX. Middle: stack bars showing the frequencies of IR− and IR+ cells among TOX+ 
memory CD8+ T cells (n = 30 HIV− donors in blue and n = 17 HIV+ viremic donors in 
red). Right: bar graphs showing the distribution of TOX+ cells among PD-1+/−GzmB+/− 
populations of CD8+ T cells (n = 30 HIV− donors and n = 17 HIV+ viremic donors). (E) 
Left: flow cytometric gating strategy for the identification of memory CD8+ T cells, 
designed to include stem cell-like clusters. Right: UMAP plots generated from 
memory CD8+ T cells after data concatenation. The colored plots show the 
distribution of memory CD8+ T cells in the UMAP space for HIV− (n = 2; blue) and 
HIV+ viremic donors (n = 2; red). (F) Left: UMAP plots showing expression intensities 
for TOX and TCF-1. Right: the same UMAP display with subpopulations colored 
using Phenograph (n = 24 clusters). (G) UMAP plots showing expression patterns for 
the indicated markers. (H) Hierarchical clustering of expression intensity (z-score) for 
each of the indicated markers in each cluster derived using Phenograph. (I) 
Distribution of clusters between HIV− (n = 2; blue) and HIV+ viremic donors (n = 2; 
red). *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 5. Expression of TOX and TCF-1 in virus-specific CD8+ T cells. (A) Left: 
flow cytometric identification of memory CD8+ T cells specific for Flu (blue), EBV 
(orange), CMV (green), or HIV (red) using MHC class I tetramers. Right: overlays 
showing the distribution of each virus-specific population in the TOX+/−TCF-1+/− 
landscape. (B) Percent expression of TOX (left) and TCF-1 (right) in virus-specific 
memory CD8+ T cells. (C) Distribution of virus-specific memory CD8+ T cells on the 
UMAP plot derived in Figure 4 (total n = 4 healthy donors). (D) Top: distribution of 
virus-specific memory CD8+ T cells among clusters derived using Phenograph. 
Bottom: summed distribution of virus-specific memory CD8+ T cells in each cluster 
derived using Phenograph. Total n = 4 healthy donors. (E) Percent expression of the 
indicated markers among virus-specific memory CD8+ T cells (total n = 45 healthy 
donors). (F) Left: coexpression of TOX versus TNF, IL-2, and perforin among CMV-
specific CD8+ T cells pre-gated on IFN-g. Right: stack bars showing the frequencies 
of TOX− and TOX+ cells among IFN-g+ virus-specific CD8+ T cells (Flu: n = 25 healthy 
donors; EBV: n = 27 healthy donors; CMV: n = 30 healthy donors; HIV: n = 25 
healthy donors). *P < 0.05, **P < 0.01, ***P < 0.001. 
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Fig. 6. Expression of TOX and TCF-1 in functional HIV-specific CD8+ T cells. (A) 
Percent expression of the indicated markers among tetramer-defined HIV-specific 
CD8+ T cells from ECs (n = 11; light red), HIV+ aviremic donors on ART (n = 15; red), 
and HIV+ viremic donors (n = 16; dark red). (B) Percent expression of TOX and TCF-
1 in tetramer-defined HIV-specific CD8+ T cells from the donor groups in A. (C) 
Colored graphs: percent frequencies of IL-2+ (left) and CD107a+ cells (right) among 
all responsive HIV-specific CD8+ T cells from the donor groups in A after stimulation 
of PBMCs with pools of peptides corresponding to known optimal epitopes derived 
from HIV. Donor-matched graphs: expression intensities of TOX and TCF-1 in IL-2− 
versus IL-2+ (left) and CD107a− versus CD107a+ HIV-specific CD8+ T cells (right). (D) 
Expression of TOX and TCF-1 in GzmB+perforin+IFN-g+ (red) and IL-2+ HIV-specific 
CD8+ T cells (blue). MFI, median fluorescence intensity. *P < 0.05, **P < 0.01, ***P < 
0.001. 
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